Martingale Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Martingale Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,084	Closed	-$192K	–	888
2023 Q1	$192K	Hold	1,084	–	–	﹤0.01%	784
2022 Q4	$419K	Buy	1,084 +759	+234%	+$288K	0.01%	656
2022 Q3	$110K	Sell	325 -378	-54%	-$137K	﹤0.01%	803
2022 Q2	$232K	Sell	703 -928	-57%	-$326K	﹤0.01%	785
2022 Q1	$714K	Buy	1,631 +201	+14%	+$82.5K	0.01%	562
2021 Q4	$627K	Buy	1,430 +70	+5%	+$35.2K	0.01%	595
2021 Q3	$757K	Buy	1,360 +367	+37%	+$184K	0.01%	577
2021 Q2	$511K	Buy	993 +675	+212%	+$428K	0.01%	586
2021 Q1	$249K	Buy	+318	New	+$218K	﹤0.01%	779

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's TVRD Position: Q2 2023 in Review

Martingale Asset Management sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 1,084 shares — an estimated $192K sold.

Martingale Asset Management first reported a position in TVRD in Q1 2021 and held it in 9 quarters. The position peaked at $757K in Q3 2021. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

Martingale Asset Management reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
Martingale Asset Management sold 1,084 Tvardi Therapeutics shares in Q2 2023, an estimated $192K.
Martingale Asset Management first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 9 quarters.
Martingale Asset Management's Tvardi Therapeutics position peaked at $757K in Q3 2021.
137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.